Advances in hidradenitis suppurativa
Transcript: What are your thoughts on the key findings for izokibep?
Martina Porter
All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
So just for background, izokibep is a IL-17A inhibitor that- and they presented their week 12 data from their phase three trial of moderate to severe patients with HS, and their primary endpoint was HiSCR75 at week 12.
And I think this is actually quite exciting and interesting, because this is the first time that we've seen data with HiSCR75 as a primary endpoint in a phase three trial. And my personal opinion about HiSCR75 versus 50 is that I think for patients, that 75% improvement is much more impactful in terms of their quality of life and their satisfaction with disease control than a 50% improvement. Even though 50% is definitely, it can make a large change for patients. What they showed is that 33% of patients that were in the study achieved HiSCR75 at week 12 and versus 21% of placebo.
And so, this was a statistically distinct or significant finding, and I think it shows a few things. One is that we can expect some of these higher thresholds of response, but we still don't see a really, really huge, I think, response rate at a 75% improvement. The second thing is that if you look closely at the curve in terms of response, it actually appears to still be rising. And although week 12 was their primary endpoint, they're actually going out to week 16 in a placebo-controlled period.
So we'll be able to see if the patients actually have an even greater response compared to placebo in the next four weeks. And so it really does, I think, validate that IL-17A is an important driver of HS disease and that we can control some of this inflammation with IL-17A inhibitors.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event
This content has been developed independently of the sponsor, UCB Biopharma SRL, which has had no editorial input into the content. EPG Health received funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.